Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform

STAMPEDE Trial Management Group

Research output: Contribution to journalArticlepeer-review


Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to current standard-of-care therapies for prostate cancer. Its use might mitigate the deleterious side effects of castration and exert an additional anticancer effect. It will be incorporated in the STAMPEDE trial platform in summer 2016. This will test its true utility as a repurposed treatment for men with high-risk locally advanced or metastatic prostate cancer at first presentation.

Original languageEnglish
Pages (from-to)906-908
Number of pages3
JournalEuropean Urology
Issue number6
Publication statusPublished - Dec 2016


  • Androgen Antagonists/adverse effects
  • Drug Repositioning
  • Drug Therapy, Combination
  • Humans
  • Hyperglycemia/chemically induced
  • Hypoglycemic Agents/therapeutic use
  • Male
  • Metformin/therapeutic use
  • Neoplasm Metastasis
  • Orchiectomy/adverse effects
  • Prostatic Neoplasms/pathology

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform'. Together they form a unique fingerprint.

Cite this